For some, mild headaches may come and go during dose changes or as their eating habits evolve
Roughly 10% of reproductive-age women are affected, which translates to approximately 190 million people globally
I think it would be helpful if there was some kind of acknowledgement that these are people that are living with a disease, and they've taken a treatment for that disease, and there is no shame in that they're improving their overall health. Evers said people need to move away from calling GLP-1 drugs weight-loss medications and instead call them obesity medications, which gives them an accurate medical context
Shele G, Genkil J, Speelman D
doi: 10.1016/j.jpsychires.2020.11.023 86 KiserC.GonulC
The 6% who stay on it for life are more likely to be diabetics. Obesity rates and behavioral changes Current obesity rates have not gone down since the use of GLP-1s has risen, Badaracco said